Identification of Attractive Drug Targets in Neglected-Disease Pathogens Using an In Silico Approach
暂无分享,去创建一个
David S. Roos | Christiane Hertz-Fowler | Santiago J. Carmona | Gregory J. Crowther | Stuart A. Ralph | Fernán Agüero | Maria A. Doyle | Solomon Nwaka | Matthew Berriman | M. Berriman | D. Roos | S. Ralph | Fernán Agüero | S. Carmona | M. Doyle | C. Hertz-Fowler | S. Nwaka | Dhanasekaran Shanmugam | W. V. Van Voorhis | Dhanasekaran Shanmugam | Wesley C. Van Voorhis
[1] A. Vaughan,et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development , 2008, Cellular microbiology.
[2] F. Joubert,et al. Structure‐based inhibitor screening: A family of sulfonated dye inhibitors for malaria parasite triosephosphate isomerase , 2001, Proteins.
[3] I. Fairweather,et al. A possible model of benzimidazole binding to beta-tubulin disclosed by invoking an inter-domain movement. , 2004, Journal of molecular graphics & modelling.
[4] Jason A. Papin,et al. Systems analysis of metabolism in the pathogenic trypanosomatid Leishmania major , 2008, Molecular systems biology.
[5] Haiming Wang,et al. SchistoDB: a Schistosoma mansoni genome resource , 2008, Nucleic Acids Res..
[6] G. Mustata,et al. A Target-Based High Throughput Screen Yields Trypanosoma brucei Hexokinase Small Molecule Inhibitors with Antiparasitic Activity , 2010, PLoS neglected tropical diseases.
[7] David Osumi-Sutherland,et al. FlyBase: enhancing Drosophila Gene Ontology annotations , 2008, Nucleic Acids Res..
[8] Patricia De la Vega,et al. Discovery of Gene Function by Expression Profiling of the Malaria Parasite Life Cycle , 2003, Science.
[9] Richard J. Marhöfer,et al. A Comparative Chemogenomics Strategy to Predict Potential Drug Targets in the Metazoan Pathogen, Schistosoma mansoni , 2009, PloS one.
[10] Karl W. Broman,et al. A postgenomic method for predicting essential genes at subsaturation levels of mutagenesis: Application to Mycobacterium tuberculosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[11] M. Lynch,et al. The altered evolutionary trajectories of gene duplicates. , 2004, Trends in genetics : TIG.
[12] Manoj Kumar,et al. Structure‐Based Design of a Novel Class of Potent Inhibitors of InhA, the Enoyl Acyl Carrier Protein Reductase from Mycobacterium Tuberculosis: A Computer Modelling Approach , 2008, Chemical biology & drug design.
[13] I. Coppens,et al. The adaptative mechanisms of Trypanosoma brucei for sterol homeostasis in its different life-cycle environments. , 2000, Annual review of microbiology.
[14] P. Michels,et al. Genetic validation of aldolase and glyceraldehyde-3-phosphate dehydrogenase as drug targets in Trypanosoma brucei. , 2010, Molecular and biochemical parasitology.
[15] Wim G J Hol,et al. Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. , 2006, Molecular and biochemical parasitology.
[16] E. Rubin,et al. Genome-wide requirements for Mycobacterium tuberculosis adaptation and survival in macrophages. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[17] Marc A. Martí-Renom,et al. MODBASE: a database of annotated comparative protein structure models and associated resources , 2005, Nucleic Acids Res..
[18] Eileen Kraemer,et al. TriTrypDB: a functional genomic resource for the Trypanosomatidae , 2009, Nucleic Acids Res..
[19] Xinxia Peng,et al. A combined transcriptome and proteome survey of malaria parasite liver stages , 2008, Proceedings of the National Academy of Sciences.
[20] John P. Overington,et al. Genomic-scale prioritization of drug targets: the TDR Targets database , 2008, Nature Reviews Drug Discovery.
[21] Antje Chang,et al. BRENDA, AMENDA and FRENDA the enzyme information system: new content and tools in 2009 , 2008, Nucleic Acids Res..
[22] R. Altman,et al. Drug Targets for Plasmodium falciparum: a post-genomic review/survey. , 2006, Mini reviews in medicinal chemistry.
[23] Christopher M. Sassetti,et al. Genetic requirements for mycobacterial survival during infection , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[24] P. Overath,et al. The molecular phylogeny of trypanosomes: evidence for an early divergence of the Salivaria. , 1998, Molecular and biochemical parasitology.
[25] T. Jones,et al. Structural basis for the inhibition of Mycobacterium tuberculosis glutamine synthetase by novel ATP-competitive inhibitors. , 2009, Journal of molecular biology.
[26] 全忠 林,et al. Trypanosoma cruzi , 1937, CABI Compendium.
[27] A. Hopkins,et al. The druggable genome , 2002, Nature Reviews Drug Discovery.
[28] J. Bennett,et al. Physiological role of HMG-CoA reductase in regulating egg production by Schistosoma mansoni. , 1989, The American journal of physiology.
[29] F. Opperdoes,et al. The Trypanosoma cruzi Proteome , 2005, Science.
[30] Midori Kato-Maeda,et al. Functional and evolutionary genomics of Mycobacterium tuberculosis: insights from genomic deletions in 100 strains. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[31] P. Michels,et al. Molecular and biochemical characterization of novel glucokinases from Trypanosoma cruzi and Leishmania spp. , 2007, Molecular and biochemical parasitology.
[32] Philip E. Bourne,et al. The RCSB PDB information portal for structural genomics , 2005, Nucleic Acids Res..
[33] Sharmila Anishetty,et al. Potential drug targets in Mycobacterium tuberculosis through metabolic pathway analysis , 2005, Comput. Biol. Chem..
[34] Wendy A. Warr,et al. ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI) , 2009, J. Comput. Aided Mol. Des..
[35] Meena Kishore Sakharkar,et al. A novel genomics approach for the identification of drug targets in pathogens, with special reference to Pseudomonas aeruginosa , 2004, Silico Biol..
[36] James R. Brown,et al. Identification of gene targets against dormant phase Mycobacterium tuberculosis infections , 2007, BMC infectious diseases.
[37] L. Holden-Dye,et al. SLO, SLO, quick, quick, slow: calcium-activated potassium channels as regulators of Caenorhabditis elegans behaviour and targets for anthelmintics , 2007, Invertebrate Neuroscience.
[38] E. Rubin,et al. Transposon site hybridization in Mycobacterium tuberculosis. , 2008, Methods in molecular biology.
[39] R. Pax,et al. Na+–K+ transport, motility and tegumental membrane potential in adult male Schistosoma mansoni , 1981, Parasitology.
[40] J. Vermunt,et al. Assessing Performance of Orthology Detection Strategies Applied to Eukaryotic Genomes , 2007, PloS one.
[41] N. Surolia,et al. Design, development, synthesis, and docking analysis of 2′‐substituted triclosan analogs as inhibitors for Plasmodium falciparum Enoyl‐ACP reductase , 2009, IUBMB life.
[42] G. H. Coombs,et al. Two pathways for cysteine biosynthesis in Leishmania major. , 2009, The Biochemical journal.
[43] Christopher J. Tonkin,et al. Dissecting Apicoplast Targeting in the Malaria Parasite Plasmodium falciparum , 2003, Science.
[44] J. Foster,et al. Mining Predicted Essential Genes of Brugia malayi for Nematode Drug Targets , 2007, PloS one.
[45] R. Martin,et al. Modes of action of anthelmintic drugs. , 1997, Veterinary journal.
[46] F. Buckner,et al. Crystal structures of trypanosomal histidyl-tRNA synthetase illuminate differences between eukaryotic and prokaryotic homologs. , 2010, Journal of molecular biology.
[47] Christopher J. Tonkin,et al. Protein Targeting to the Malaria Parasite Plastid , 2007, Traffic.
[48] John P. Overington,et al. The genome of the blood fluke Schistosoma mansoni , 2009, Nature.
[49] H. Hwang,et al. Genetic Analysis of Purine Metabolism in Leishmania donovani * , 1997, The Journal of Biological Chemistry.
[50] Ross S Hall,et al. Drug target prediction and prioritization: using orthology to predict essentiality in parasite genomes , 2010, BMC Genomics.
[51] Feng Chen,et al. OrthoMCL-DB: querying a comprehensive multi-species collection of ortholog groups , 2005, Nucleic Acids Res..
[52] Samiul Hasan,et al. Prioritizing Genomic Drug Targets in Pathogens: Application to Mycobacterium tuberculosis , 2006, PLoS Comput. Biol..
[53] John P. Overington. ChEMBL. An interview with John Overington, team leader, chemogenomics at the European Bioinformatics Institute Outstation of the European Molecular Biology Laboratory (EMBL-EBI). Interview by Wendy A. Warr. , 2009, Journal of computer-aided molecular design.
[54] E. Rubin,et al. Genes required for mycobacterial growth defined by high density mutagenesis , 2003, Molecular microbiology.
[55] L. A. Basso,et al. One-step purification of 5-enolpyruvylshikimate-3-phosphate synthase enzyme from Mycobacterium tuberculosis. , 2003, Protein expression and purification.
[56] Barbara M. Bakker,et al. Experimental and in Silico Analyses of Glycolytic Flux Control in Bloodstream Form Trypanosoma brucei* , 2005, Journal of Biological Chemistry.
[57] Dhilon S. Patel,et al. Shape‐ and Chemical Feature‐Based 3D‐Pharmacophore Model Generation and Virtual Screening: Identification of Potential Leads for P. falciparum DHFR Enzyme Inhibition , 2010, Chemical biology & drug design.
[58] Alok Bhattacharya,et al. Inhibitors of Escherichia coli serine acetyltransferase block proliferation of Entamoeba histolytica trophozoites. , 2008, International journal for parasitology.
[59] Eileen Kraemer,et al. PlasmoDB: a functional genomic database for malaria parasites , 2008, Nucleic Acids Res..
[60] Solomon Nwaka,et al. Innovative lead discovery strategies for tropical diseases , 2006, Nature Reviews Drug Discovery.
[61] Kalidas Yeturu,et al. targetTB: A target identification pipeline for Mycobacterium tuberculosis through an interactome, reactome and genome-scale structural analysis , 2008, BMC Systems Biology.
[62] M. Mather,et al. Mitochondrial drug targets in apicomplexan parasites. , 2007, Current drug targets.
[63] P. Selzer,et al. A combined bioinformatics and chemoinformatics approach for the development of new antiparasitic drugs. , 2007, Genomics.